

Natco Pharma Limited

Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

24th May, 2022

Corporate Relationship Department M/s. BSE Ltd Dalal Street, For, Mumbai 400001

Scrip Code: 52481

Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza, Bandra Kurla Complex Bandra East, <u>Mumbai 400051</u>

Scrip Code: NATCOPHARM

Dear Sir

Sub: - FY22 Financial Results Earnings Call

The Company will host an Earnings Call with Investors / Analysts at **11.00 a.m. IST on Tuesday, 31**st **May, 2022, at 11:00 AM IST** to disseminate Financial Results of the company for the quarter and year ended March 31, 2022.

A Copy of the same is enclosed for your ready reference

Thanking you

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer

NATCO PHARMA

Hosted by Edelweiss Securities



India Equity Research May 24, 2022

Edelweiss Securities is hosting a conference call with the management of Natco Pharma to discuss the Company's Q4FY22 financial results on Tuesday, May 31 2022 at 11.00 AM IST.

Mr. Rajeev Nannapaneni, Director & Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President – Crop Health Sciences will represent Natco Pharma on the call.

Details of the conference call are as under:

Time : 11.00PM IST on Tuesday, May 31, 2022

Conference dial-in:			
India	:	Mumbai	
		Primary access number	+ 91 22 6280 1123
			+91 22 7115 8024
USA	:		1 866 746 2133
UK	:		0 808 101 1573
Singapore Toll Free No.	:		800 101 2045
Hong Kong Toll Free No.	:		800 964 448

Call leader Mr. Kunal Randeria

For further information please contact:

Kunal Randeria

Edelweiss Securities Ltd. Tel.: +91 22 6620 3040 Fax: +91 22 2286 4310

E-mail: kunal.randeria@edelweissfin.com

Express Join with <u>DiamondPass™</u>